JTX 2011

Drug Profile

JTX 2011

Alternative Names: JTX-2011

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jounce Therapeutics
  • Class Antineoplastics; Cell therapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Inducible T-cell co-stimulator protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 08 Mar 2018 Jounce Therapeutics plans a a new combination trial of JTX 2011 and a CTLA-4 inhibitor in 2018
  • 05 Jun 2017 Adverse events data from the phase I/II ICONIC trial in Solid tumours released by Jounce Therapeutics
  • 02 Jun 2017 Pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top